Loading clinical trials...
Loading clinical trials...
An Open-label Clinical Trial of Ex Vivo Beta-globin Lentiviral Vector Transduction of Autologous CD34+HSPCs (Vebeglogene Autotemcel) for the Treatment of Transfusion Dependent Beta-thalassemia Patients
Conditions
Interventions
Vebeglogene autotemcel
Locations
2
China
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Kunming, Yunnan, China
Kunming Hope of Health Hospital
Kunming, Yunnan, China
Start Date
May 11, 2024
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
November 25, 2025
NCT06647979
NCT03653338
NCT06772766
NCT06606886
NCT05762510
NCT06328764
Lead Sponsor
Lantu Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions